



Antimicrobial Susceptibility Profile (July 1, 2025 through June 30, 2026)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory, Clinics, and Physician Offices.

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

	Achromobacter xylosoxidans		Acin.baumannii complex ^a		Citro. freundii complex ^b		Citrobacter koserii		Ent. cloacae complex ^c		Escherichia coli		E. coli (ESBL)		Klebsiella (Ent) aerogenes ^d		Klebsiella oxytoca		Klebsiella pneumoniae		Kleb pneumo (ESBL)		Klebsiella variicola		Morganella morganii		Proteus hauseri		Proteus mirabilis		Providencia rettgeri		Pseudo aeruginosa		S.marcescens complex ^e	
	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun
Amikacin	7	*			100	100			100	100	100	100	100	100	100	100	100	100	100	100	100	99	100	100			*	*	100	100	100		100 ^f	100 ^f	100	100
Ampicillin											63	62																	89	91						
Ampicillin/Sulbactam			99	99							91	88					98	97	92	91			97	93	18	12	*	*	99	98	64	81				
Cefazolin (non-urine)											85	83							92	85									70	73						
Cefazolin (urine)											96	96							97	96									98	98						
Cefepime	40	*	96	99	99	100	100	100	97	99	100	100			100	100	100	100	100	100			100	100			*	*	100	100	97	100	98	99	100	99
Ceftazidime																																	98	97		
Ceftriaxone	14	*			84	87	99	99			99	99			90	92	100	100	99	99			99	99			*	*	100	100	100	100			89	91
Ciprofloxacin	40	*	96	96	94	92	98	100			83	81	19	25	98	98	98	99	96	96	15	12	100	100	88	88	*	*	95	95	94	94	92	93	92	98
Ertapenem					98	100	100	100	100	100	100	100	100	100	99	100	100	100	100	100	99	98	100	100	100	99	*	*	100	100	100	100			100	99
Gentamicin	10	*			97	98	100	100	99	99	93	93	67	67	100	100	100	100	100	99	80	80	100	100	97	96	*	*	96	97	97	94			100	100
Levofloxacin	89	*			98	100	100	100	96	98	84	83	23	30	100	100	100	100	98	98	27	20	100	100	99	99	*	*	100	100	100	100			93	99
Meropenem			99	100	99	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	99	99	100	100	100	99	*	*	100	100	100	100	96	98	100	99
Minocycline			100	100																																
Nitrofurantoin (urine)					95	98	97	99	65	64	99	99	99	98	33	30			61	52	44	20														
Piperacillin/Tazobactam	94	*	96	97	88	89	100	100			98	98	95 ^g	97 ^g	91	93	99	100	97	96	80 ^g	72 ^g	98	97	97	96	*	*	100	100	94	94				
Tobramycin	63	*	95	99																												100	99			
Trimeth-Sulfa	50	*	97	96	88	88	99	99	90	90	84	82	40	45	97	98	95	93	95	95	25	13	98	97	94	91	*	*	91	92	86	94			100	99
Total Isolates	32	28	90	70	68	90	254	263	303	272	7555	6555	802	780	186	165	83	82	1604	1409	148	158	92	69	144	159	23	19	903	804	35	52	1224	1186	112	129
Total # Urine Isolates	11	3	27	17	49	64	202	206	146	130	7262	6308	737	720	145	125	58	60	1420	1251	116	132	78	61	96	89	12	7	665	621	15	29	318	285	35	29
											E.coli (ESBL) rate		10%	11%			K.pneumo (ESBL) rate		8%	10%																

Percent susceptible calculations are based on total isolates.
Percent susceptible calculations for drugs specified as "urine" are based on total # urine isolates.

FOOTNOTES:
a *Acinetobacter baumannii* complex includes *A.calcoacecus*, *A.baumannii*, *A.dijkshoomiae*, *A.lactucae*, *A.nosocomialis*, *A.pittii* and *A. seifertii*
b *Citrobacter freundii* complex includes *C.braaki*, *C.freundii*, *C.gillenii*, *C.murlinia*, *C.rodenticum*, *C.sedlakii* and *C.wekmenii*
c *Enterobacter cloacae* complex includes *E.asburiae*, *E.cancerogenus*, *E.cloacae*, *E.dissolvens*, *E.hormaechei*, *E.kobei*, *E.ludwigii* and *E.nimipressuralis*
d *Enterobacter aerogenes* has been renamed *Klebsiella aerogenes*
e *Serratia marcescens* complex includes *S. marcescens*, *S.nemotophila* and *S.ureilytica*
f For urine only with isolates of *Pseudomonas aeruginosa*
g For urine only with isolates of ESBL

<i>Stenotrophomonas maltophilia</i>	Jul-Dec	Jan-Jun
Levofloxacin	87	92
Minocycline	98	97
Trimethoprim/Sulfa	92	91
Total Isolates	66	76
Total # Urine Isolates	7	15

	Jul-Dec	Jan-Jun
<i>Haemophilus influenzae</i>		
Ampicillin	75	72
Ampicillin/Sulbactam	96	96
Azithromycin	100	100
Ceftriaxone	100	99
Ciprofloxacin	100	100
Levofloxacin	100	100
Meropenem	100	100
Trimethoprim/Sulfa	50	55
Total Isolates	53	82
Total # Urine Isolates	3	5

Asterisk (*) indicates no result available
Where isolates in both periods are >=30, the following apply:
Green indicates increase in susceptibility by >5%
Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinically significant and is not provided. These are highlighted in BLUE on these tables.
Source: CLSI Document M39-5thEd, January 2022



Antimicrobial Susceptibility Profile (July 1, 2025 through June 30, 2026)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory, Clinics, and Physician Offices.

GRAM POSITIVE SUSCEPTIBILITIES (Percent Susceptible)

S.aureus complex includes S.aureus, S. argenteus and S. schweitzeri	S. aureus ^c complex MSSA		S. aureus complex MRSA		All S. aureus complex		Staph lugdunensis		All other Staph sp. coag neg		Enterococcus Non-VRE ^d		Enterococcus faecalis		Enterococcus faecium		Enterococcus VRE		Streptococcus agalactiae		Streptococcus pneumoniae		Streptococcus pyogenes		Streptococcus viridans Group ^f			
	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun		
Ampicillin											94	97	100	100	40	54	5	10	100	100			100	100	100	98		
Cefazolin	100	100			74	74	81	84	58	56									100	100			100	100	100	98		
Cefotaxime																					See Table				99	98		
Ceftriaxone																			100	100	See Table		100	100	99	98		
Ciprofloxacin (urine)											90	92	94	93	38	*	*	*										
Clindamycin ^a	85	84	68	68	80	80	*	*	63	62									53	46	74	81	85	83				
Daptomycin ^b	100	100	100	100	100	100	100	100	100	100																		
Doxycycline		99		96		99		100		91																		
Erythromycin ^a	77	76	41	40	68	66	*	*	42	45									47	44	68	67	84	82				
Levofloxacin (urine)											90	93	95	94	35	*	*	*										
Linezolid	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100										
Minocycline ^a	100		100		100		*		98																			
Moxifloxacin																					100	100						
Nitrofurantoin (urine)	100	100	*	100	100	100	*	*	100	100	96	98	100	100	35	*	*	*										
Oxacillin	100	100			74	74	80	84	58	56																		
Penicillin	39				29		40		23		93		100		40		2		100	100	See Table		100	100	98	97		
Tetracycline	91	91	71	68	87	85	93	96	76	77	24°	25°	23°	24°	40°	*°	*°	*°			56	86	77	67				
Trimeth-Sulfa	92	93	66	65	85	86	97	100	75	76											79	93						
Vancomycin	100	100	100	100	100	100	100	100	100	100	96	99	100	100	100	100	0	0			100	100			100	100		
Total Isolates	2109	2018	798	704	3035	2722	58	50	1115	1050	1390	1269	1236	1178	101	39	42	40	113	116	39	43	913	617	137	160		
Total # Urine Isolates	129	145	24	33	153	178	29	29	473	477	964	924	883	878	65	24	27	27	14	10	1	0	0	0	35	48		
	MRSA Rate		27%	26%											VRE Rate		3%	3%										

Streptococcus pneumoniae								
Cefotaxime			Ceftriaxone			Penicillin		
MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae	
	Jul-Dec	Jan-Jun		Jul-Dec	Jan-Jun		Jul-Dec	Jan-Jun
<=0.12	35	38	<=0.12	34	37	<=0.06	29	34
0.25	0	0	0.25	1	1	0.12	2	0
0.5	2	3	0.5	2	4	0.25	3	3
1	1	2	1	0	1	0.5	1	1
2	1	0	2	2	0	1	2	3
>=4	0	0	>=4	0	0	2	0	2
						4	2	0
						>=8	0	0

S. pneumoniae interpretive guidelines

Penicillin		
Parenteral non-meningitis		
<=2 S	4 I	>=8 R
Parenteral meningitis		
<=0.06 S	----	>=0.12 R
Oral		
<=0.06 S	0.12-1 I	>=2 R
Cefotaxime and Ceftriaxone		
Non-meningitis		
<=1 S	2 I	>=4 R
Meningitis		
<=0.5 S	1 I	>=2 R

Percent susceptible calculations are based on total isolates.
Percent susceptible calculations for drugs specified as "urine" are based on total # urine isolates.

FOOTNOTES:

a Clindamycin, Erythromycin & Minocycline are not appropriate for urine sources

b Daptomycin not reported for lower respiratory tract

c *Staph aureus* (MSSA) isolates that show Penicillin susceptibility may harbor the blaZ gene that produces beta-lactamase.

d Non-VRE includes intrinsically resistant *Enterococcus* (*E. casseliflavus* & *E.gallinarum*)

e For urine only with isolates of *Enterococcus*

f *Viridans Strep* Group includes *S. anginosus* group, *S.bovis* group, *S.mitis* group, *S.mutans* group, *S.salivarius* group, and *S.sanguinis* group

Asterisk (*) indicates no result available

Where isolates in both periods are >=30, the following apply:

Green indicates increase in susceptibility by >5%

Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinically significant and is not provided. These are highlighted in BLUE on these tables.

Source: CLSI Document M39-5thEd, January 2022